Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study

BackgroundDotinurad is a novel selective urate transporter 1 (URAT1) inhibitor recently introduced in Japan. This study aims to evaluate the efficacy and safety of dotinurad in hyperuricemic patients with type 2 diabetic kidney disease by comparing serum levels of urate and plasma and urinary levels...

Descripció completa

Dades bibliogràfiques

Autors principals:	Takeshi Osonoi, Shinichiro Shirabe, Miyoko Saito, Mitsuru Hosoya, Norie Watahiki, Satako Douguchi, Kensuke Ofuchi, Makoto Katoh
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2025-10-01
Col·lecció:	Frontiers in Endocrinology
Matèries:	febuxostat dotinurad type 2 diabetic kidney disease urate excretion transporter serum urate urate transporter 1 (URAT1)
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1655502/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!